Together, these observations and the current findings related to AZGP1 indicate that increasing leptin sensitivity could be a potential therapeutic strategy to combat obesity-associated metabolic disorders. This evidence concerns the gene AZGP1 and obesity due to melanocortin 4 receptor deficiency.